Key Highlights
- Rocket Pharmaceuticals received FDA accelerated approval for KRESLADI, a gene therapy targeting severe leukocyte adhesion deficiency-I (LAD-I) in pediatric patients.
- Shares of RCKT surged up to 9% during premarket hours on Friday, maintaining approximately 6% gains at market open.
- This marks the inaugural FDA-approved gene therapy for severe LAD-I, an ultra-rare and potentially fatal immune disorder affecting children.
- The company received a Rare Pediatric Disease Priority Review Voucher from the FDA, which Rocket intends to sell for additional capital.
- The authorization follows a previous FDA rejection in June 2024 that required supplementary clinical data.
Rocket Pharmaceuticals secured FDA authorization for its gene therapy KRESLADI on Friday, propelling RCKT shares up to 9% during premarket hours before stabilizing at approximately 6% gains by market opening.
Rocket Pharmaceuticals, Inc., RCKT
The authorization followed an accelerated pathway, indicating the agency based its decision on preliminary evidence — particularly elevated neutrophil CD18 and CD11a surface expression levels. Complete verification of therapeutic effectiveness will require extended data collection from a continuing clinical trial and a mandatory post-approval registry.
KRESLADI, scientifically designated as marnetegragene autotemce, represents an autologous hematopoietic stem cell-based gene therapy. The treatment received approval for children diagnosed with severe LAD-I resulting from biallelic variants in the ITGB2 gene, specifically those lacking access to an HLA-matched sibling donor for stem cell transplantation.
LAD-I represents an exceptionally rare inherited immunodeficiency disorder. The condition triggers repeated infections and demonstrates elevated mortality rates during early childhood when left untreated. Within the United States, occurrence rates approximate one case per 100,000 to 200,000 live births, with severe manifestations accounting for roughly two-thirds of diagnoses.
KRESLADI now stands as the inaugural FDA-authorized gene therapy addressing this medical condition.
The path to approval encountered obstacles. The FDA initially rejected the biologics license application during June 2024, requesting Rocket provide supplementary data before finalizing the regulatory assessment.
Rocket resubmitted the BLA, receiving FDA acceptance in October 2024, with March 28, 2026 established as the target decision date — a timeline the regulatory body honored.
Priority Review Voucher Provides Additional Revenue Opportunity
Accompanying the authorization, the FDA awarded Rocket a Rare Pediatric Disease Priority Review Voucher. These instruments can be transferred to other pharmaceutical manufacturers for valuations reaching hundreds of millions of dollars and represent a substantial financial benefit beyond the approval alone.
Rocket announced plans to assess opportunities for monetizing the voucher to strengthen its financial position.
“The approval of KRESLADI represents an important milestone for the severe LAD-I community,” said CEO Gaurav Shah.
Research Development Background
Investigation supporting KRESLADI’s advancement received partial funding from the California Institute for Regenerative Medicine. The therapeutic agent targets the ITGB2 gene, which produces a protein crucial for white blood cell immune response functionality.
The Cranbury, New Jersey-headquartered biotechnology company has pursued this approval over multiple years.
The FDA’s decision deadline for the resubmitted BLA was March 28, 2026, and the regulatory agency authorized the therapy precisely on schedule.
